Compare · ABBV vs NEPT
ABBV vs NEPT
Side-by-side comparison of AbbVie Inc. (ABBV) and Neptune Wellness Solutions Inc. (NEPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and NEPT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $394.12B, about 7603.4x NEPT ($51.8M).
- ABBV has hit the wire 10 times in the past 4 weeks while NEPT has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 0 for NEPT).
- Company
- AbbVie Inc.
- Neptune Wellness Solutions Inc.
- Price
- $223.01-1.80%
- $0.20-47.23%
- Market cap
- $394.12B
- $51.8M
- 1M return
- +10.05%
- -
- 1Y return
- +17.97%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Neptune Wellness Solutions Inc.
Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest NEPT
- Neptune Wellness Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Neptune Securities Settlement Fund sold $13,601 worth of shares (200,300 units at $0.07), decreasing direct ownership by 25% to 1,048,334 units (SEC Form 4)
- SEC Form 25-NSE filed by Neptune Wellness Solutions Inc.
- Neptune Wellness Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Neptune Wellness Solutions Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits
- Neptune Wellness Solutions Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Neptune Appoints Interim President, CEO, Interim COO
- Neptune Appoints Interim President and CEO and Interim COO
- Cannabis Stock Gainers And Losers From March 7, 2024
- Neptune Wellness Solutions Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits